跳至主要内容
临床试验/CTRI/2019/07/020435
CTRI/2019/07/020435尚未招募Phase 3 4

Double ARM Randomised Controlled Study Comparing the Efficacy of Platelet Rich Plasma and Local Application of 2% THBG (Alpha Glucoside Derivative of Trihydroxy Benzoic Acid) in Patients with Facial Melasma.

Government medical college bhavnagar1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年1月8日最近更新:

试验速览

阶段
Phase 3 4
状态
尚未招募
入组人数
60
试验地点
1
主要终点
Physician global assessment scale

研究概览

简要总结

Melasma is the most common cause of facial melanosis  and is manifested by hyperpigmented macules on the face which become more pronounced after sun exposure

Transforming growth factor Beta 1(TGF B1) is present in Alfa granules of platelets

It is known to decrease melanogenesis via delayed extracellular signal-regulated kinase activation

Thba

Controls NF-kB pathway

Reduces PGE2 expression

Prevents melanin transfer to keratinocytes

Inhibits Tyrosinase

研究设计

研究类型
Interventional
分配方式
Random Number Table
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • patients with age above 18 years irrespective of their sex clinically diagnosed melasma will be included in study .

排除标准

  • Females on oral contraceptive pill Age <18 years Pregnant female Tendency for keloid, hypertrophic scar Bleeding disorder Platelet abnormality On anticoagulant drugs Chronic liver disease On oral tretinoin Refusal to allow photographs hiv/hbsag +ve.

结局指标

主要结局

Physician global assessment scale

时间窗: after 6 weeks

MelasQOL(melasma quality of life)

时间窗: after 6 weeks

dermoscope

时间窗: after 6 weeks

Modified melasma area severity index

时间窗: after 6 weeks

Patients global assessment scale

时间窗: after 6 weeks

次要结局

  • dermoscopic and woods lamp dignosis of melasma(improvement in masi and melaqol)

研究者

申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验